Insider Purchases: Inside the Buy
Tag: Short Interest
🚢 Norwegian Cruise Line (NCLH): Why Insiders Just Bought $27M of Stock
Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.
TTD Stock Analysis 2026: Jeff Green’s $148M Bet — Is The Trade Desk the Ultimate “Buy the Dip” Play?
The Trade Desk just got the loudest kind of bullish signal: the founder-CEO bought $148M of his own stock after an 80%+ drawdown. Institutions are stacked, shorts are circling, and valuation has finally cooled from “bubble” to “business.” The question now: is TTD a generational dip… or a beautiful trap?
DKNG Stock Deep Dive 2026: Insider Buying, Q4 Earnings, and the “Matrix” Growth Play
DraftKings isn’t just a sportsbook anymore—it’s becoming an “internet casino layer” built on attention, probability, and habit loops. With a major insider purchase, heavy institutional ownership, improving margins, and the stock still far below its highs, DKNG may be entering its most interesting chapter yet.
Enphase Energy: The Comeback Nobody Believed (But the CEO Keeps Buying)
Enphase Energy fell hard after its solar boom—but the CEO keeps buying, institutions still dominate the float, and shorts are piled in. Here’s why ENPH might be starting to sync back in—and what investors should really watch. 🌞🔋
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Insiders Buy Mercer’s Stock, But Who Will Have Mercy on MERC?
Insiders are buying Mercer International (MERC), valuation screens look broken, and shorts are circling. Cheap stock — or classic value trap? 🌲📉
Insider Buys: Should You Root for Sprout Social — Or Be-Leaf It’s a Loon’s Call?
Sprout Social fell from SaaS stardom to near all-time lows — but insiders are buying, institutions own the float, and valuation looks compelling. Is SPT a fallen tree… or a healthy sapling ready to regrow?
Fiserv: Can Its Clover Come with Four Leaves Or Is It Just Three for Faith, Hope, and Love?
Insiders are buying, institutions are loading up, shorts are barely awake, and Fiserv now trades at deep-value multiples. With Clover, cash flow, and a credible turnaround plan, is this three-leaf fintech about to sprout a fourth? 🍀